EUVIMEDEUVIMED entdecken
Open Access

lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma

Qiang Wang, GuangJun Xiao, Na Li, Xiulin Jiang, Chunhong Li

Aging · 2023

DOI: 10.18632/aging.204756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging, 2023. Verfasst von Qiang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Surgical Unit, Suining Central Hospital, Suining 629000, Sichuan, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, RNA, Long Noncoding, Adenocarcinoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Integrin alpha L (ITGAL) seemed to play a critical role in carcinogenesis and immune regulation. Nevertheless, the effects of ITGAL on non-small cell lung cancer (NSCLC) remain elusive. The present paper intended to determine the effects of ITGAL in NSCLC via the integration of bioinformatic analyses. In this study, we found that the mRNA and protein levels of ITGAL were downregulated in NSCLC tissues. Significantly, low ITGAL expression was related to poorer prognosis and increased malignancy of NSCLC. In addition, GO analysis and KEGG pathway analysis revealed that the coexpressed genes of ITGAL were predominantly associated with various immune-associated signaling pathways, like the T cell receptor signaling pathway, Th17 cell differentiation, chemokine signaling pathway, and NF-κB signaling pathway. Our result indicated that lncRNA-mediated downregulation of integrin alpha L expression was tightly related to immunocyte infiltration, immune modulators, and chemotactic factors in NSCLC, which potentially serves as a biomarker for clinical prognosis prediction and immunotherapy of NSCLC. This is the first comprehensive analysis of ITGAL in the prognosis, immune microenvironment, and immunotherapy of lung adenocarcinoma. ITGAL are promising biomarkers for predicting clinical outcomes and immunotherapy responses in patients with NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsRNA, Long NoncodingAdenocarcinomaHumansPrognosisDown-RegulationIntegrinsLungTumor MicroenvironmentDNA-Binding ProteinsRNA-Binding Proteins

Stichwörter der Autor:innen

NSCLCimmune checkpoint inhibitorsimmunotherapyintegrin alpha LlncRNA

Substanzen

RNA, Long NoncodingIntegrinsPCBP1 protein, humanDNA-Binding ProteinsRNA-Binding Proteins

Autor:innen und Institutionen

  • Gastrointestinal Surgical Unit, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
  • Department of Clinical Laboratory Medicine, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
  • Department of Oncology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.

Zitieren

APA

Wang, Q., Xiao, G., Li, N., Jiang, X., & Li, C. (2023). lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma. Aging. https://doi.org/10.18632/aging.204756

Vancouver

Wang Q, Xiao G, Li N, Jiang X, Li C. lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma. Aging. 2023. doi:10.18632/aging.204756

BibTeX
@article{Wang2023,
  author = {Wang, Qiang and Xiao, GuangJun and Li, Na and Jiang, Xiulin and Li, Chunhong},
  title = {lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma},
  journal = {Aging},
  year = {2023},
  doi = {10.18632/aging.204756}
}
Kostenlos starten →